Feasibility evaluation of emodin (rhubarb extract) as an inhibitor of pancreatic cancer cell proliferation in vitro

Journal of Parenteral and Enteral Nutrition

Volumn 32, Issue 2, 2008, Pages 190-196

  Cai, Jun ^a   Razzak, Anthony ^a   Hering, Justin ^a   Saed, Abdul ^a   Babcock, Tricia A ^a   Helton, Scott ^a   Espat, N Joseph ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Cellular proliferation; Emodin; Pancreatic cancer

Indexed keywords

EMODIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROPIDIUM IODIDE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; FEASIBILITY STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; RHUBARB;

ADENOCARCINOMA; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EMODIN; FLOW CYTOMETRY; HUMANS; PANCREAS; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; RHEUM; TREATMENT OUTCOME;

AGOUTI PACA; RHEUM X HYBRIDUM;

EID: 41549158208     PISSN: 01486071     EISSN: None     Source Type: Journal    
DOI: 10.1177/0148607108314371     Document Type: Article

References (23)

1. Espat NJ, Brennan MF, Conlon KC Patients with laparoscopically staged unresectable pancreatic adenocarcinoma do not require subsequent surgical biliary or gastric bypass. J Am Coll Surg. 1999 ; 188: 649-655.
2. Stathopoulos GP, Syrigos K., Polyzos A., et al. Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study. Ann Oncol. 2004 ; 15: 224-229.
3. Carnero A. Targeting the cell cycle for cancer therapy. Br J Cancer. 2002 ; 87: 129-133.
4. Jing X., Ueki N., Cheng J., Imanishi H., Hada T. Induction of apoptosis in hepatocellular carcinoma cell lines by Emodin. Jpn J Cancer Res. 2002 ; 93: 874-882.
5. Hu W., Kavanagh JJ Anticancer therapy targeting the apoptotic path-way. Lancet Oncol. 2003 ; 4: 721-729.
6. Demirezer LO, Kuruuzum-Uz A., Bergere I., Schiewe HJ, Zeeck A. The structures of antioxidant and cytotoxic agents from natural source: anthraquinones and tannins from roots of Rumex patientia. Phytochemistry. 2001 ; 58: 1213-1217.
7. Wang HH, Chung JG Emodin-induced inhibition of growth and DNA damage in the Helicobacter pylori. Curr Microbiol. 1997 ; 35: 262-266.
8. Chang CH, Lin CC, Yang JJ, Namba T., Hattori M. Anti-inflammatory effects of emodin from ventilago leiocarpa. Am J Chin Med. 1996 ; 24: 139-142.
9. Huang HC, Chang JH, Tung SF, Wu RT, Foegh ML, Chu SH Immunosuppressive effect of emodin, a free radical generator. Eur J Pharmacol. 1992 ; 211: 359-364.
10. Sato M., Maulik G., Bagchi D., Das DK Myocardial protection by protykin, a novel extract of trans-resveratrol and Emodin. Free Radic Res. 2000 ; 32: 135-144.
11. Goel RK, Das Gupta G., Ram SN, Pandey VB Antiulcerogenic and anti-inflammatory effects of emodin, isolated from Rhamnus triquerta wall. Ind J Exp Biol. 1991 ; 29: 230-232.
12. Srinivas G., Anto RJ, Srinivas P., Vidhyalakshmi S., Senan VP, Karunagaran D. Emodin induces apoptosis of human cervical cancer cells through poly(ADP-ribose) polymerase cleavage and activation of caspase-9. Eur J Pharmacol. 2003 ; 473: 117-125.
13. Chen YC, Shen SC, Lee WR, et al. Emodin induces apoptosis in human promyeloleukemic HL-60 cells accompanied by activation of caspase 3 cascade but independent of reactive oxygen species production. Biochem Pharmacol. 2002 ; 64: 1713-1724.
14. Jayasuriya H., Koonchanok NM, Geahlen RL, McLaughlin JL, Chang CJ Emodin, a protein tyrosine kinase inhibitor from Polygonum cuspidatum. J Nat Prod. 1992 ; 55: 696-698.
15. Zhang L., Lau YK, Xi L., et al. Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neuinduced cellular transformation and metastasis-associated properties. Oncogene. 1998 ; 16: 2855-2863.
16. Zhang L., Chang CJ, Bacus SS, Hung MC Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin. Cancer Res. 1995 ; 55: 3890-3896.
17. Lee HZ Protein kinase C involvement in aloe-emodin and emodin induced apoptosis in lung carcinoma cell. Br J Pharmacol. 2001 ; 134: 1093-1103.
18. Lee HZ Effects and mechanisms of emodin on cell death in human lung squamous cell carcinoma. Br J Pharmacol. 2001 ; 134: 11-20. 19. Jayasuriya H., Koonchanok NM, Geahlen RL, McLaughlin JL, Chang CJ Emodin, a protein tyrosine kinase inhibitor from Polygonum cuspidatum. J Nat Prod. 1992 ; 55: 696-698.
19. Yi J., Yang J., He R., et al. Emodin enhances arsenic trioxide-induced apoptosis via generation of reactive oxygen species and inhibition of survival signaling. Cancer Res. 2004 ; 64: 108-116.
20. Zhang L., Lau YK, Xia W., Hortobagyi GN, Hung MC Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin Cancer Res. 1999 ; 5: 343-353.
21. Su YT, Chang HL, Shyue SK, Hsu SL Emodin induces apoptosis in human lung adenocarcinoma cells through a reactive oxygen species-dependent mitochondrial signaling pathway. Biochem Pharmacol. 2005 ; 70: 229-241.
22. Wang W., Abbruzzese JL, Evans DB, Larry L., Cleary KR, Chiao PJ The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res. 1999 ; 5: 119-127.
23. Fahy BN, Schlieman MG, Virudachalam S., Bold RJ Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer. J Am Coll Surg. 2004 ; 198: 591-599.